Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Nathalie Pognan"'
Autor:
Xiaoming, Cui, Xinhui, Chen, Nathalie, Pognan, Tirtha, Sengupta, Gholamreza, Rahmanzadeh, Ruediger, Kornberger, Monica, Giovannini
Publikováno v:
The Journal of Clinical Pharmacology. 63:228-238
Capmatinib is a highly specific, potent, and selective mesenchymal-epithelial transition factor inhibitor predominantly eliminated by cytochrome P450 (CYP) 3A4 and aldehyde oxidase. Here, we investigated the effects of a strong CYP3A inhibitor (itrac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9783f9507c285890559d6e4b22f1b401
https://doi.org/10.1002/jcph.2153
https://doi.org/10.1002/jcph.2153
Autor:
Xinhui Chen, Nicolas Isambert, Rafael López‐López, Monica Giovannini, Nathalie Pognan, Shruti Kapoor, Michelle Quinlan, Benoit You, Xiaoming Cui, Gholamreza Rahmanzadeh, Morten Mau‐Sorensen
Publikováno v:
Chen, X, Isambert, N, López-López, R, Giovannini, M, Pognan, N, Kapoor, S, Quinlan, M, You, B, Cui, X, Rahmanzadeh, G & Mau-Sorensen, M 2023, ' Effect of capmatinib on the pharmacokinetics of substrates of CYP3A (midazolam) and CYP1A2 (caffeine) in patients with MET-dysregulated solid tumours ', British Journal of Clinical Pharmacology, vol. 89, no. 3, pp. 1046-1055 . https://doi.org/10.1111/bcp.15544
Background: Preclinical studies showed that capmatinib reversibly inhibits cytochrome P450 (CYP) 3A4 and CYP1A2 in a time-dependent manner. In this study, we evaluated the effect of capmatinib on the exposure of sensitive substrates of CYP3A (midazol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e751618123039bf7c0a8151dbb589a3e
https://curis.ku.dk/portal/da/publications/effect-of-capmatinib-on-the-pharmacokinetics-of-substrates-of-cyp3a-midazolam-and-cyp1a2-caffeine-in-patients-with-metdysregulated-solid-tumours(72512f3f-33d1-4b5e-974b-4b8e0ef1d394).html
https://curis.ku.dk/portal/da/publications/effect-of-capmatinib-on-the-pharmacokinetics-of-substrates-of-cyp3a-midazolam-and-cyp1a2-caffeine-in-patients-with-metdysregulated-solid-tumours(72512f3f-33d1-4b5e-974b-4b8e0ef1d394).html
Autor:
Xinhui Chen, Michelle Quinlan, Shruti Kapoor, Xiaoming Cui, Thomas Marbury, Nathalie Pognan, Gholamreza Rahmanzadeh, Monica Giovannini
Publikováno v:
British journal of clinical pharmacology. 88(1)
Capmatinib, a mesenchymal-epithelial transition factor tyrosine kinase inhibitor, is metabolized by cytochrome P450 (CYP) 3A4 and aldehyde oxidase. In individuals with hepatic impairment, alterations in hepatobiliary excretion and metabolism could le
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f424d59a3346ff8a8224c803e2e36cb7
https://pubmed.ncbi.nlm.nih.gov/34046915
https://pubmed.ncbi.nlm.nih.gov/34046915
Autor:
Lin Yang, Jordi Rodon, Patrick Y. Wen, Warren P. Mason, Nathalie Pognan, Joseph T. Beck, H. Hirte, Mark Rosenthal, Pedro Pérez Segura, Lucia Trandafir, Charu Kanwal, John DeGroot
BACKGROUND: Phase I, two-stage study of buparlisib combined with standard-of-care (RT + TMZ followed by adjuvant TMZ) in newly diagnosed GBM. METHODS: Stage I evaluated buparlisib with adjuvant TMZ in 28-day treatment cycles after prior RT + TMZ trea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0fe8d55d0b65f7ae8520743a109ae90b
https://europepmc.org/articles/PMC4638534/
https://europepmc.org/articles/PMC4638534/